Table 1.
Baseline characteristics of all participants
| 7-day STT | 10-day BQT | P value | |
|---|---|---|---|
| (n = 177) | (n = 175) | ||
| Age (year), Mean ± SD | 55.6 ± 11.3 | 53.9 ± 10.7 | 0.147 |
| Sex, no. (%) | 0.920 | ||
| Male | 83 (46.9) | 83 (47.4) | |
| Female | 94 (53.1) | 92 (52.6) | |
| Smoking, no. (%) | 0.196 | ||
| Never | 116 (65.5) | 103 (58.9) | |
| Current or former smoker | 61 (34.5) | 72 (41.1) | |
| Alcohol, no. (%) | 0.028 | ||
| Never | 82 (46.3) | 61 (34.9) | |
| Current or former alcohol drinker | 95 (53.7) | 114 (65.1) | |
| Family history of gastric cancer, no. (%) | 65 (36.7) | 61 (34.9) | 0.715 |
| Coexisting illness, no. (%) | |||
| Hypertension | 37 (20.9) | 43 (24.6) | 0.412 |
| Diabetes mellitus | 11 (6.2) | 13 (7.4) | 0.651 |
| Indications for H. pylori treatment, no. (%) | |||
| Post-ESD for adenoma or gastric cancer | 55 (31.1) | 51 (29.1) | 0.693 |
| Peptic ulcer disease | 22 (12.4) | 27 (15.4) | 0.416 |
| Chronic gastritis with non-ulcer dyspepsia | 100 (56.5) | 97 (55.4) | 0.840 |
STT, proton-pump inhibitor-clarithromycin containing standard triple therapy; BQT, bismuth-containing quadruple therapy; SD, standard deviation; ESD, endoscopic submucosal dissection